Publications by authors named "F Demirkan"

Claim this Profile
C
Comment on: How early is early for JIA? Insights from the infantile-onset juvenile idiopathic arthritis patients of the PERA research group cohort: Reply.
Kubra Ozturk, Tuncay Aydin, Gulcan Ozomay Baykal, Esra Baglan, Hulya Kose, Fatma Gul Demirkan

Rheumatology (Oxford)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic therapy through caregivers' eyes: insights from a multicenter pediatric rheumatology survey.
Büşra Başer Taşkın, Ayşenur Doğru Kılınç, Muhammed Talha Karadoğan, Figen Çakmak, Fatma Gül Demirkan

Expert Opin Biol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.
Ibrahim Ethem Pinar, Serhat Celik, Merve Gokcen Polat, Aylin Fatma Karatas, Ali Dogan, Fatih Demirkan

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Fatih Demirkan

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry.
Volkan Karakus, Ibrahim Ethem Pinar, Utku Iltar, Emel Merve Yenihayat, Merve Gokcen Polat, Fatih Demirkan

J Clin Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis